From the euphoric highs of 2018’s ‘green rush’ to the sharp corrections and structural stasis that have followed, cannabis equities have been among the most volatile financial assets since they first appeared on global markets.
Behind the headline swings lie three core drivers: fragmented regulation, capital market misalignment, and investor sentiment cycles.
Even as legalisation advances, the volatility is unlikely to vanish until the sector’s fundamentals – earnings, banking, and institutional access – catch up with optimism.
The Anatomy of Volatility: Structural Drivers
Fragmented and shifting regulation
In the US, cannabis remains a Schedule I substance under the Controlled Substances Act, meaning federal illegality remains in place despite widespread state legalisation.
That discrepancy creates continual uncertainty: will reform happen? When? How will interstate commerce, banking and tax treatment change? The mere hint of reform triggers sharp equity moves.
Similarly, in Canada and Europe, legalisation and regulated markets have advanced, yet regulatory roll-out remains slow, fragmented by province or nation, and often lacking scale. For the capital markets, this means valuations built on reform expectations remain exposed to timing risk.
For example, the very structure of US cannabis ETFs, such as those tracking multistate operators, often requires creative structures (swaps, Canadian listings) because US exchanges and banks restrict plant-touching operators. That structural handicap feeds into valuation risk and thus volatility.
In Europe, the regulatory patchwork is even more pronounced, and stark changes in policy and sentiment can happen even more quickly. Germany is a prime example of this dynamic.
Since 2023, Germany has swung from being Europe’s leading candidate for full, Canada-style legalisation, to sustaining a fast-growing but fragile medical market, and now to a more defensive posture as the government signals potential policy tightening.
This consistent shifting of policy, outlook and sentiment, rather than any reliable continuation or consistent direction, means stocks are largely built on hope, move fast and then correct abruptly.
Access to banking, capital markets and market liquidity
One of the under-appreciated drivers of cannabis stock volatility is access, not just to consumers, but to capital, banking, payment infrastructure and institutional capital.
Leafy Tunnel Hopes To Pave The Way For ‘More Institutional Capital’ In European Cannabis Industry
Read More »Because the federal status in the US limits many mainstream banks and brokers from serving cannabis companies, many of these firms list in Canada, OTC or on smaller exchanges, thereby reducing liquidity, analyst coverage and institutional access.
That creates a market in which smaller, less liquid stocks trade on sentiment proxies rather than fundamentals.
Higher cost of capital (due to perceived regulatory risk) also means many operators carry elevated debt, burn cash, and face refinancing risk. Any weak earnings or reform delay becomes a trigger for sharp stock moves.
Data from the Montréal Exchange illustrates this point: implied volatility on major cannabis equities frequently exceeded 80% during the 2018–2019 period, compared with around 10% for the broader S&P/TSX Composite Index.
The combination of thin liquidity, speculative investor ownership and structural capital hurdles ensures that even modest negative signals can provoke outsized share price responses.
Investor base and sentiment cycles
Cannabis equities, particularly in the early phase, were dominated by retail-driven flows, limited institutional support and narratives of imminent reform or beverage/consumer convergence.
The ‘green rush’ narrative attracted speculative capital and created momentum moves. Yet when fundamentals lagged expectations, value erosion followed quickly.
In 2018, the surge in investment was dramatic. Some reports cited around US$10 billion of investment into North American cannabis in 2018 alone.
Retail participation often amplifies volatility: momentum chasing followed by rapid exits when sentiment turns. As one analyst put it, cannabis stocks ‘giveth and … taketh away’.
With institutional participation still hesitant (given regulatory, tax and banking risks), the sector remains vulnerable to sentiment-led swings rather than steadier, fundamentals-based flows.
Weak fundamentals, pricing pressure and valuation distortion
Fundamental performance in many cannabis businesses remains challenged. As seen in Canada, licensed producers, riding this tidal wave of ‘green rush’ cash and sentiment rapidly expanded capacity in anticipation of adult-use demand, only to find slower retail rollout, stronger illicit market competition and evolving price compression.
That meant margins, profits, and growth often fell significantly short of expectations. This dynamic has largely been in a period of correction ever since.
For US operators, tax and banking burdens reduce leverage and profitability. That makes traditional valuation metrics less reliable, increasing the chance of swings: good news rallies trigger hopes of profitability, bad news triggers sharp de-rating.
One structural tax headwind in the US, the now-notorious Internal Revenue Code Section 280E, prevents many cannabis businesses from deducting ordinary business expenses from gross income because cannabis is federally illegal. It is also a key driver of excitement around the US rescheduling project, which would do away with 280E.
That can push effective tax rates above 50-70%, even in loss-making operations. Because many companies trade on expectations of reform rather than proven earnings, the risk premium remains high, and valuations thus remain sensitive to shifts in expectations.
Supply-demand imbalances and margin levers
The ‘green rush’ was characterised by high optimism, expanding capacity and visible potential gains. But supply often outpaced demand.
In Canada, large greenhouse projects were built ahead of retail rollout; inventory build-up followed, impairments were taken, and the market recalibrated. That structural mismatch translated into earnings risk and, therefore, stock price risk.
Macro sensitivity and risk-on / risk-off dynamics
Given the speculative nature of many cannabis equities, they behave more like high-beta growth stocks than mature consumer goods or pharma companies.
That makes them vulnerable to broader capital market swings, meaning interest-rate rises, liquidity tightening, and bearish sentiment tend to hit these stocks first.
Conversely, reform optimism, retail hirings and M&A speculation can drive exaggerated upside. In short, cannabis stocks amplify rather than dampen market cycles.
Case Studies: Illustrating Volatility
Case Study 1: Canada’s Licensed Producers Over-build
Canadian companies rushed to build large greenhouse capacity ahead of adult-use roll-out and export opportunities. For example, one Canadian LP built 800,000 sq ft+ greenhouses only to pause operations in 2020 after sales disappointed.
“Quite frankly, I would be concerned if they weren’t selling it at this point,” Andrew Carter, cannabis analyst, Stifel Financial Corp.
The mismatch between capacity and demand forced impairments and margin compression, which shocked valuations that had been built on growth assumptions, not on profitability. The result: stocks that had been trading at 80–100× earnings went into free-fall when earnings failed to materialise.
Case Study 2: US Multi-State Operators (MSOs) Depressed by Barriers
MSOs in the US, though reporting strong growth in states, remain unable to access many traditional banking services, cannot list on major US exchanges in many cases and face federal tax burdens (see Section 280E above). As a result, even operationally strong MSOs appear financially weaker on paper, leaving their valuations highly sensitive to reform news.
For example, Curaleaf Holdings, the largest US operator by revenue, generated over US $1.3 billion in 2024 sales but still trades at a market capitalisation below US $3 billion, less than three times revenue.
Comparable consumer-packaged-goods or alcohol companies typically trade at multiples of six to ten times. This discount reflects the cost of limited market access and investor risk perception.
Case Study 3: Oxford Cannabinoid Technologies and the European Liquidity Trap
The collapse of Oxford Cannabinoid Technologies (OCT) in October 2024 captured the fragility of Europe’s cannabis equity market. Once a symbol of scientific credibility within the sector, OCT’s fall highlights how thin liquidity, weak institutional backing and investor fatigue continue to amplify volatility across the region.
OCT listed on the London Stock Exchange in May 2021, raising £16.5 million and debuting at a valuation of around £51 million.
It aimed to develop cannabinoid-based, non-addictive pain therapies, positioning itself more as a biotech than a traditional cannabis stock. Yet by 2024, that distinction no longer shielded it from broader sentiment shifts.
Daily trading volumes were consistently negligible, leading to small sell-offs that triggered sharp price declines. At the same time, European investors mirrored sentiment from North America, where declining valuations and stalled reform dampened appetite for cannabis-linked assets.
By 2024, OCT’s share price had fallen more than 90% from its IPO spike. Its collapse underscores how European cannabis stocks remain trapped in a feedback loop of low liquidity and imported volatility.
Outlook: A Gradual Path to Stability
Volatility in cannabis equities is unlikely to disappear overnight, but positive regulatory developments and the maturation of the industry will continue to gradually reduce the size and impact of these pendulum swings.
As the evolution of this young market continues, companies that’ve proven their ability to withstand such adverse conditions will, by nature, have stronger and more dependable balance sheets and business models.
This will provide a much more attractive investment opportunity for larger investment firms, relinquishing the market’s reliance on retail investors, further reducing volatility.
But the barriers, both reputational and systemic, which prevent institutional funds from entering the market remain.
Should the Trump administration move to complete its predecessor’s cannabis rescheduling project, this will go some way to opening the door for these investors, and could help clear the path for companies to trade on larger exchanges like NASDAQ.
In Europe, there has been a marked shift towards the prioritisation of pharmaceutical practice and positioning. While this involves significant upfront capital, it helps remove the risks associated with the early cannabis industry in the eyes of investors.
As more clinical research emerges, and markets like France integrate medical cannabis into the national health system, the dial will continue to shift in the industry’s favour.
Over the past eight years, the cannabis industry has demonstrated remarkable resilience, continuing to expand despite shrinking capital flows and persistent regulatory uncertainty. The exuberance of the 2018 green rush has given way to a more disciplined phase, shaped by consolidation, operational efficiency and policy reform.
For investors, the sector is unlikely to deliver the speculative surges once associated with its early years, or with high-risk assets such as cryptocurrency. But as the industry matures and financial infrastructure catches up with demand, volatility should gradually ease. The longer-term opportunity lies not in short-term rallies, but in patient exposure to a sector moving steadily from promise to performance.
